Synthesis, anticonvulsant activity and 5-HT1A/5-HT7 receptors affinity of 1-[(4-arylpiperazin-1-yl)-propyl]-succinimides

Pharmacological Reports

Volumn 64, Issue 2, 2012, Pages 326-335

  Obniska, Jolanta ^a   Chlebek, Iwona ^a   Kamiński, Krzysztof ^a   Bojarski, Andrzej J ^b   Satała, Grzegorz ^b  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

3,3 disubstituted pyrrolidine 2,5 diones; Anticonvulsant activity; Arylpiperazines

Indexed keywords

1 [3 (4 PHENYLPIPERAZIN 1 YL)PROPYL] 3 ETHYL 3 METHYLPYRROLIDINE 2,5 DIONE MONOHYDROCHLORIDE; 1 [3 [4 (2 CHLOROPHENYL) PIPERAZIN 1 YL]PROPYL] 3 ETHYL 3 METHYLPYRROLIDINE 2,5 DIONE MONOHYDROCHLORIDE; 1 [3 [4 (2 CHLOROPHENYL)PIPERAZIN 1 YL]PROPYL] 3 METHYL 3 PHENYLPYRROLIDINE 2,5, DIONE MONOHYDROCHLORIDE; 1 [3 [4 (2 FLUOROPHENYL) PIPERAZIN 1 YL]PROPYL] 3 ETHYL 3 METHYLPYRROLIDINE 2,5 DIONE MONOHYDROCHLORIDE; 1 [3 [4 (2 FLUOROPHENYL)PIPERAZIN 1 YL]PROPYL] 3 METHYL 3 PHENYLPYRROLIDINE 2,5, DIONE MONOHYDROCHLORIDE; 1 [3 [4 (2 METHOXYPHENYL) PIPERAZIN 1 YL]PROPYL] 3 ETHYL 3 METHYLPYRROLIDINE 2,5 DIONE MONOHYDROCHLORIDE; 1 [3 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]PROPYL] 3 METHYL 3 PHENYLPYRROLIDINE 2,5, DIONE MONOHYDROCHLORIDE; 1 [3 [4 (3 CHLOROPHENYL) PIPERAZIN 1 YL]PROPYL] 3 ETHYL 3 METHYLPYRROLIDINE 2,5 DIONE MONOHYDROCHLORIDE; 1 [3 [4 (3 CHLOROPHENYL)PIPERAZIN 1 YL]PROPYL] 3 METHYL 3 PHENYLPYRROLIDINE 2,5, DIONE MONOHYDROCHLORIDE; 1 [3 [4 (3 TRIFLUOROMETHYLPHENYL) PIPERAZIN 1 YL]PROPYL] 3 ETHYL 3 METHYLPYRROLIDINE 2,5 DIONE MONOHYDROCHLORIDE; 1 [3 [4 (3 TRIFLUOROMETHYLPHENYL)PIPERAZIN 1 YL]PROPYL] 3 METHYL 3 PHENYLPYRROLIDINE 2,5, DIONE MONOHYDROCHLORIDE; 1 [3 [4 (4 CHLOROPHENYL) PIPERAZIN 1 YL]PROPYL] 3 ETHYL 3 METHYLPYRROLIDINE 2,5 DIONE MONOHYDROCHLORIDE; 1 [3 [4 (4 CHLOROPHENYL)PIPERAZIN 1 YL]PROPYL] 3 METHYL 3 PHENYLPYRROLIDINE 2,5, DIONE MONOHYDROCHLORIDE; 1 [3 [4 (4 FLUOROPHENYL) PIPERAZIN 1 YL]PROPYL] 3 ETHYL 3 METHYLPYRROLIDINE 2,5 DIONE MONOHYDROCHLORIDE; 1 [3 [4 (4 FLUOROPHENYL)PIPERAZIN 1 YL]PROPYL] 3 METHYL 3 PHENYLPYRROLIDINE 2,5, DIONE MONOHYDROCHLORIDE; ANTICONVULSIVE AGENT; PHENYTOIN; SEROTONIN 1A RECEPTOR; SEROTONIN 7 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; MOUSE; NONHUMAN; RAT; SEIZURE; TOXICITY TESTING;

EID: 84862214322     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(12)70772-7     Document Type: Article

References (32)

1. 7R ligands: Synthesis and biological evaluation. Bioorg Med Chem Lett, 2009, 19, 1600-1603.
2. Barton ME, Klein BD, Wolf HH, White HS: Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res, 2001, 47, 217-227. (Pubitemid 34008465)
3. Brodie M J: Antiepileptic drug therapy the story so far. Seizure, 2010, 19, 650-655.
4. Brown WC, Schiffman DO, Swinyard EA, Goodman LS: Comparative assay of an antiepileptic drugs by psychomotor seizure test and minimal threshold test. J Pharmacol Exp Ther, 1953, 107, 273-289.
5. Cheng Y, PrusoffWH: Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol, 1973, 22, 3099-3108.
6. Dunham NW, Miya TA: A note on a simple apparatus for detecting neurological deficit in rats and mice. J Am Pharm Assoc Sci, 1957, 46, 208-209.
7. 1A serotonin ligands. J Med Chem, 1988, 31, 1968-1971.
8. A receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice. Epilepsia, 2004, 45, 864-873.
9. Kamiński K, Obniska J: Design, synthesis and anticonvulsant activity of N-phenylamino derivatives of 3.3-dialkylpirolidine- 2,5-diones and hexahydro-isoindole-1,3-diones. Bioorg Med Chem, 2008, 16, 4921-4931. (Pubitemid 351625890)
10. Kamiński K, Obniska J: Synthesis and anticonvulsant properties of new N-pyridine-2-yl 3-substituted pirolidine-2,5-dione derivatives. Acta Pol Pharm Drug Res, 2008, 65, 457-465.
11. Katritzky AR, Satheesh KN, Witek RM, Hutchins SM: Synthesis of 3,3-diarylpyrrolidines from diaryl ketones. ARKIVOC, 2003, (v), 9-18. (Pubitemid 38904465)
12. Khan H N, Kulsoom S, Rashid H: Ligand based pharmacophore model development for the identification of novel antiepileptic compound. Epilepsy Res, 2012, 98, 62-71.
13. Krall RL, Penry JK, White BG, Kupferberg HJ, Swinyar EA: Antiepileptic drug development II. Anticonvulsant drug screening. Epilepsia, 1978, 19, 400-428.
14. Kupferberg HJ: Antiepileptic drug development program: a cooperative effort of government and industry. Epilepsia, 1989, 30, Suppl, 51-56.
15. Leopoldo M, Lacivita E, Berardi F, Perrone R, Hedlund PB: Serotonin 5-HT7 receptor agents: Structure-activity relationships and potential therapeutic applications in central system disorders. Pharmacol Ther, 2011, 129, 120-148.
16. 7 receptor ligands. Eur J Med Chem, 2011, 4, 3348-3361.
17. 1A receptors. Curr Med Chem, 2002, 9, 443-469.
18. Löscher W: Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure, 2011, 20, 359-368.
19. Mirski M, Ziai W, Chiang J, Hinich M, Sherman D: Anticonvulsant serotonergic and deep brain stimulation in anterior thalamus. Seizure, 2009, 18, 64-70.
20. Obniska J, Byrtus H, Kamiński K, Pawł owski M, Szczȩsio M, Karolask-Wojciechowska J: Design, synthesis, and anticonvulsant activity of new N-Mannich bases derived from spirosuccinimides. Bioorg Med Chem, 2010, 18, 6134-6142.
21. Obniska J, Chlebek I, Pichór J, Kopytko M, Kamiński K: Synthesis, physicochemical and anticonvulsant properties of new N-[(4-arylpiperazin-1-yl)-alkyl]-3-phenyland 3-(3-methylphenyl)-pyrrolidine-2,5- diones. Acta Pol Pharm Drug Res, 2009, 66, 639-647.
22. Obniska J, Jurczyk S, Zejc A, Kamiński K, Tatarczyńska, Stachowicz K: Anticonvulsant properties of N-(4-methylpiperazin- 1-yl) and N-[(4-methylpiperazin-1-yl)-propyl] derivatives of 3-aryl and 3-spirocycloalkyl-pyrrolidine- 2,5-dione. Pharmacol Rep, 2005, 57, 170-175.
23. Obniska J, Kamiński K, Skrzyńska D, Pichór J: Synthesis and anticonvulsant activity of new N-[(4-arylpiperazin- 1-yl)-alkyl]-derivatives of 3-phenylpyrrolidine-2,5-dione. Eur J Med Chem, 2009, 44, 2224-2233.
24. Obniska J, Kamiński K, Tatarczyńska E: Impact of aromatic substitution on the anticonvulsant activity of new N-(4-arylpiperazin-1-yl)- alkyl-2-azaspiro[4.5]decane- 1,3-dione derivatives. Pharmacol Rep, 2006, 58, 207-214.
25. Obniska J, Kopytko M, Zagórska A, Chlebek I, Kamiński K: Synthesis and anticonvulsant activity of new Mannich bases derived from 3-aryl-pyrrolidine-2,5-diones. Arch Pharm, 2010, 343, 333-341.
26. Obniska J, Kulig K, Zejc A: Synthesis and anticonvulsant properties of new 4-piperazinylalkyl imides of succinic acid. Acta Pol Pharm Drug Res, 1998, 55, 223-231. (Pubitemid 28353701)
27. Obniska J, Zagorska A: Synthesis and anticonvulsant properties of new N-[(4-arylpiperazin-1-yl)-methyl] derivatives of 3-aryl pyrrolidine-2,5-dione and 2-aza-spiro[4.4]nonane-1,3- dione. Farmaco, 2003, 58, 1227-1234. (Pubitemid 37433845)
28. 7 receptor affinity and in vivo pharmacological properties of some new1-(m- trifluoromethylphenylpiperazines. Bioorg Med Chem, 2007, 15, 7116-7125.
29. 7 receptors in the control of seizures. Brain Res, 2007, 1141, 48-55.
30. Perucca E, Tomson T: The pharmacological treatment of epilepsy in adults. Lancet Neurol, 2011, 10, 446-456.
31. Thirumurugan R, Sriram D, Saxena A, Stables J, Yogeeswari P: 2,4-Dimetoxyphenylsemicarbazones with anticonvulsant activity against tree animal models of seizures: Synthesis and pharmacological evaluation. Bioorg Med Chem, 2006, 14, 3106-3112.
32. Yogeeswari P, Sriram D, Thirumurugan R, Raghavendran J, Sudhan K, Pavana P, Stables J: Discovery of N-(2,6-dimethylphenyl)-substituted semicarbazones as anticonvulsants: hybrid pharmacophore-based design. J Med Chem, 2005, 48, 6202-6211. (Pubitemid 41428975)